BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Boehringer Ingelheim
Medtronic
Dow
Daiichi Sankyo
Chinese Patent Office
Cipla
Johnson and Johnson
Argus Health
McKesson

Generated: January 22, 2018

DrugPatentWatch Database Preview

RAPAFLO Drug Profile

« Back to Dashboard

Which patents cover Rapaflo, and when can generic versions of Rapaflo launch?

Rapaflo is a drug marketed by Allergan Sales Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has six patent family members in four countries.

The generic ingredient in RAPAFLO is silodosin. There are twelve drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the silodosin profile page.
Summary for RAPAFLO
International Patents:6
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 4
Bulk Api Vendors: 62
Clinical Trials: 7
Patent Applications: 284
Drug Prices:see details
DailyMed Link:RAPAFLO at DailyMed
Drug patent expirations by year for RAPAFLO
Pharmacology for RAPAFLO

US Patents and Regulatory Information for RAPAFLO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for RAPAFLO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-001 Oct 8, 2008 ➤ Subscribe ➤ Subscribe
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for RAPAFLO
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules 4 mg and 8 mg ➤ Subscribe 10/9/2012

Supplementary Protection Certificates for RAPAFLO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0036 France ➤ Subscribe PRODUCT NAME: SILODOSIN; REGISTRATION NO/DATE IN FRANCE: EU/1/09/608/001 DU 20100129; REGISTRATION NO/DATE AT EEC: EU/1/09/608/001 DU 20100129
C/GB10/031 United Kingdom ➤ Subscribe PRODUCT NAME: SILODOSIN, OPTIONALLY IN A FORM OF A PHARMACEUTICAL ACCEPTABLE SALT; REGISTERED: UK EU/1/09/607/001-014 20100129; UK EU/1/09/608/001-014 20100129
00454 Netherlands ➤ Subscribe PRODUCT NAME: SILODOSIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/09/607/001-014EU/1/09/608/001-014 2010290129
90028-0.L Sweden ➤ Subscribe PRODUCT NAME: SILODOSIN ELLER FARMACEUTISKA GODTAGBARA SALTER DAERAV; REG. NO/DATE: EU/1/09/607/001-014 " EESGODKLANDKOD="EG" EESGODKDATUM="2010-01-29" SEGODKNR="EU/1/09/607/001-014 " SEGODKLANDKOD="EG" SEGODKDATUM="2010-01-29" FLAG="L" SPCNR="1090028-0" 20100129
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
US Department of Justice
Moodys
Mallinckrodt
US Army
Boehringer Ingelheim
Federal Trade Commission
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot